Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE

Size: px
Start display at page:

Download "Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE"

Transcription

1 LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion: NONE 1

2 Topics Introduction Whom to Test What to Test When to Test My Choosing Wisely Suggestions Introduction 2

3 Recurrence Triangle 3 months Long-term VTE due to major transient risk factor Woman with VTE on hormones Non-major transient risk factor Woman with unprovoked VTE DVT PE Man with unprovoked VTE DVT PE - D-dimer + Strong Thrombophilia [Choosing Wisely ; Hicks LK, et al. Hematology Am Soc Hematol Educ Program. 2014;2014: ] ACCP, AHA, ISTH, BJH 3

4 Strong Thrombophilias 1. APLA syndrome 2. Antithrombin deficiency 3. Protein C deficiency 4. Protein S deficiency 5. Homozygous factor V Leiden 6. Homozygous II20210 mutation 7. Heterozygous FVL plus heterozygous II20210 Yes yes / no unknown yes / no [Segal J et al. JAMA 2009; 301: ] [Lijfering WM et al. Circulation 2010;121: ] [Garcia D et al. Blood 2013;122: ] Recurrence Triangle Cumulative VTE Recurrence Rate 1 year 5 years 3 months Long-term VTE due to major transient risk factor Woman with VTE on hormones Non-major transient risk factor Woman with unprovoked VTE DVT PE Man with unprovoked VTE DVT PE 1 % 3 % 6 % * 5 % 15 % 10 % 30 % [Kearon C et al. Blood 2014;123: ] *[Douketis J et al. BMJ 2011;342:d813] 4

5 Downsides of Thrombophilia Testing Take-home point 1. Don t over-focus on the thrombophilia Clinic Patient 39 year old woman Proximal arm DVT and PE 4/2016 VTE risk factors: (a) hetero FV Leiden, (b) hetero II20210 mutation. FH: Parents with VTE. Neither one of them has factor V or factor II. 5

6 Clinic Patient Mother Father Downsides of Thrombophilia Testing 1. Don t over-focus on the thrombophilia 2. Caveat: Wrong test ordered 3. Caveat: Misinterpretation of tests 6

7 Decision Making Based on Thrombophilia 62 year old proximal leg DVT 3 weeks after hip replacement surgery APLA testing positive = life-long anticoagulation Downsides of Thrombophilia Testing 1. Don t over-focus on the thrombophilia 2. Caveat: Wrong test is ordered 3. Caveat: Misinterpretation of tests 4. Caveat: Wrong/questionable decision making based on test result 7

8 Cost $ $ $ $ $ $ $ 2, Cost $

9 Downsides of Thrombophilia Testing 1. Don t over-focus on the thrombophilia 2. Caveat: Wrong test is ordered 3. Caveat: Misinterpretation of tests 4. Caveat: Wrong decision making based on test result 5. Be aware of cost of testing What to Test? Whom to Test? 9

10 Inherited and Acquired Thrombophilias Most common Classics Acquired Others Factor V Leiden Prothrombin Protein C deficiency Protein S deficiency Antithrombin deficiency Antiphospholipid antibodies (ACA, LA, anti-β 2 -GPI) Homocysteine, MTHFR Fibrinogen, factor VIII, IX, XI PAI-1, tpa levels and polymorphisms CBC, CD55/59, JAK-2 + CALR Whom to Test Controversial Guideline in development: ASH 2015, ongoing Terminology used: testing can be considered benefit of testing unclear lack of evidence that testing impacts clinical outcomes 10

11 Whom to Test for Thrombophilia? Everybody Any pt Any pt with Young pt Young pt Nobody with VTE spontan. VTE with FHx Ultra-liberal Nihilist In Whom I Consider Testing DVT/PE, intermediate risk recurrence VTE in unusual locations, unprovoked Arterial thrombosis, unexplained VTE: Patient requests testing Family members (if strong thrombophilia in index pt) No Pregnancy loss(es), unexplained 11

12 Recurrence Triangle 3 months Long-term VTE due to major transient risk factor Woman with VTE on hormones Non-major transient risk factor Woman with unprovoked VTE DVT PE Man with unprovoked VTE DVT PE - D-dimer + Strong Thrombophilia [Choosing Wisely ; Hicks LK, et al. Hematology Am Soc Hematol Educ Program. 2014;2014: ] ACCP, AHA, ISTH, BJH Recurrence Triangle In VTE patients: In intermediate risk-of-recurrence patients I consider testing 12

13 Risk of 1 st VTE with thrombophilias Relative risk increase for first VTE No thrombophilia Reference group II20210, hetero 3.8 (95% CI ) FVL, heterozygous 4.9 (95% CI ) II20210, homozygous Insufficient data FVL, homozygous 18 (95% CI ) Hetero II20210 PLUS 20 (95% CI ) hetero FVL Protein S deficiency 30.6 (95% CI ) Protein C deficiency 24.1 (95% CI ) Antithrombin deficiency 28.2 (95% CI ) [Moll S. J Thromb Thrombolys 2015; ;39(3):367-78] Risk of Recurrent VTE with Thrombophilias 1 II20210, hetero: 1.45 FVL, hetero: 1.56 (95% CI ) (95% CI ) [Segal J et al. JAMA 2009; 301: ] 2 FVL, homo: 2.65 (95 % CI ) FVL, homo: 1.2 (95 % CI ) [Segal J et al. JAMA 2009; 301: ; meta-analysis] [Lijfering WM et al. Circulation 2010;121: ] 3 FVL + II2010: 4.81 (95 % CI ) FVL + II2010: 1.0 (95 % CI ) [Segal J et al. JAMA 2009; 301: ; meta-analysis] [Lijfering WM et al. Circulation 2010;121: ] 4 II20210, homo: insufficient data 13

14 Risk of Recurrent VTE with Thrombophilias 5 Protein C Protein S Antithrombin 2.8 (95 % CI ) [Lijfering WM et al. Circulation 2010;121: ] 6 APLA: 1.41 ACA: 1.53 LA: 2.83 (95 % CI ) (95 % CI ) (95 % CI ) [Garcia D et al. Blood 2013;122: ] APLA syndrome: 2.0 [Kearon C et al; Chest 2012;141:e419S-494S] Protein C, S and Antithrombin Deficiency How do you test? C, S, AT activity free S antigen >100 mutations Acquired deficiency: Liver disease (C, S, AT) How do you treat? Consider AT concentrate Severe neonatal C deficiency: protein C concentrate Warfarin therapy (C, S) Estrogens, pregnancy (S) Inflammatory diseases (S) Heparin therapy (AT) Acute thrombosis (S, AT) 14

15 Antiphospholipid Antibodies APLA I) Antibody test (ELISA) LA ACA anticardiolipin anti-ß2-glycoprotein I antiphosphatidylserine antiphosphatidylcholine antiphosphatidylethanolamine Anti-ß2-GP I II) Functional test lupus anticoagulant (inhibitor) [Sapporo criteria: Miyakis S. J Thromb Haemost. 2006;4: ] APLA: Sapporo/Sydney Criteria Updated Sapporo Criteria for APS (2006): Clinical criteria: Vascular thrombosis Pregnancy morbidity Laboratory criteria*: Anticardiolipin antibodies (IgG or IgM) (medium or high titer: >40 GPL/MPL or >99th percentile) Anti-β 2 -glycoprotein I antibodies (IgG or IgM) (>99th percentile) LA *2 or more occasions, >12 wks apart. [Miyakis S, et al. J Thromb Haemost. 2006;4: ] [J Thromb Haemost May;12(5):792-5] 15

16 APLA: Risk for 1 st Thrombosis Conclusions: 1. LA stronger and more definitive risk factor for thrombosis than ACA. 2. Risk for thrombosis is highest if positive APLA by multiple assays. [Galli M, et al. Blood. 2003;101: ; Ruffatti A, et al. Thromb Haemost. 2006;96: ] Are APLA a Risk Factor for Recurrent VTE? Systematic Review 8 eligible studies All had important methodologic limitations. We judged the overall quality of the evidence as very low. Conclusion Although it appears that pos. APLA predict d risk of VTE recurrence, the strength of this association is uncertain. [Garcia D et al. Blood 2013;122: ] 16

17 Risk for Recurrent VTE 1. Are APLA a risk factor for recurrent VTE? They appear to be! [Garcia D et al. Blood 2013;122: ] Risk for Recurrent VTE 2. Which of the APLA best predicts recurrent VTE? LA ACA [Garcia D et al. Blood 2013;122: ] 17

18 APLA: Practical Points APLA syndrome : question the diagnosis moderately high titers of ACA ( 40 U/mL) Include anti-β 2 -GP-I antibody testing Test outside the acute event Repeat APLA testing (3 months apart) Know the LA tests and their interpretation Role of IgA antibodies unclear Homocysteine, MTHFR MTHFR C677T, homozygous TT, or A1298C May have higher homocysteine levels Not a risk factor for thrombosis or pregnancy complications Practical point: Don t Test for MTHFR. Practical point: Test for homocysteine? no good indication. MTHFR=methylenetetrahydrofolate reductase [den Heijer MJ. Thromb Haemost. 2005;3: ] [Klerk M. JAMA. 2002;288: ] [Rey E. Lancet. 2003;361: [ACOG Bulletin #124, 2011] 18

19 Factor VIII Factor VIII NOT a useful clinical tool to predict recurrent VTE Arterial thromboembolism 19

20 Unexplained Arterial Thrombosis 1. Arteriosclerosis documented or risk factors present? 2. Cardioembolic source? 3. Other causes (hormones, cocaine, vasculitis, etc?) 4. Thrombophilia? [Moll S. J Thromb Thrombolys 2015; ;39(3):367-78] Arterial Thrombosis FVL: OR 1.21 (95% CI, ) II20210: OR 1.32 (95% CI, OR ) [Kim RJ et al. Am Heart J 2003;146: ] Protein C and S deficiency <55 yrs: 4.7-fold (95 % CI ) >55 yrs: 1.1-fold (95 % CI ) Antithrombin deficiency Not a risk factor Mahmoodi BK, et al. Circulation. 2008;118: ] 20

21 Unexplained Arterial Thrombosis How to best treat (secondary prevention)? 1. Anti-platelet therapy? 2. Anticoagulant? 3. Both together? When to Test? 21

22 Influence of Anticoagulants on Thrombophilia Tests [Moll S. J Thromb Thrombolys 2015;39: ] When To Test $

23 Which Family Members to Test for Thrombophilia Multi-factorial Nature of VTE Fam H/o VTE Thrombophilia (mild, strong ) Hormones Body mass index Smoking What is this ASYMPTOMATIC family member s ABSOLUTE risk for VTE? Previous surgeries, fractures, pregnancies, hormone use WITHOUT VTE [Noboa S, et al. Thromb Res. 2008;122: ] 1. [Bezemer ID, et al. Arch Intern Med. 2009;169: ] 23

24 Which Family Members to Consider for Thrombophilia Screening? Proband s thrombophilia Male Family Member Female Family Member Sons Brothers Daughters Sisters Hetero FVL or hetero prothrombin no no no no Homo FVL or homo prothrombin no reasonable no yes Double hetero reasonable reasonable yes yes C, S, AT reasonable reasonable yes yes Reasonable reasonable because: consider LMWH with airline travel, cast, non-major surgery; prolonged after major surgeries. yes Yes because: advise against estrogen contraceptives/hormone therapy; give anteand postpartum anticoagulation Pregnancy Loss and Other Poor Pregnancy Outcomes 24

25 Pregnancy Loss / Complications [Skeith L et al. Blood 2016;127:1650-5] Pregnancy Loss / Complications All trials Multicenter trials only [Skeith L et al. Blood 2016;127:1650-5] 25

26 1 2 Pregnancy loss + thrombophilia (other than APLA): LMWH treatment NOT indicated. Pregnancy loss: thrombophilia testing NOT indicated (other than APLA) ACOG [Obstet Gynecol 2013 Sep;122(3):706-17] 1 Inherited thrombophilias Testing NOT recommended for recurrent pregnancy loss, placental abruption, IUGR or preeclampsia 2 APLA Testing may be appropriate for women with fetal loss 26

27 My Choosing Wisely Suggestions My Choosing Wisely Suggestions My 15 Choosing Wisely Suggestions a) For health care professionals b) For clinical laboratories c) For hospital systems 27

28 My Choosing Wisely Suggestions Thrombophilia Testing Do NOT test. 1. during an acute thrombotic episode. 2. a hospitalized patient. 3. while patient is on an anticoagulant. 4. if not able to interpret the test or don t know what to do with the results. 28

29 Summary 1 Often little/no evidence of benefit of testing 2 Whom to test? Unexplained unusual venous thrombosis 3. Unexplained arterial clot in the young 3 When to test: NOT acutely, NOT inpatient, NOT on anticoagulation. Summary Inherited and Acquired Thrombophilias Most common Classics Acquired Others Factor V Leiden Prothrombin Protein C deficiency Protein S deficiency Antithrombin deficiency Antiphospholipid antibodies (ACA, LA, anti-β 2 -GPI) Homocysteine, MTHFR Fibrinogen, factor VIII, IX, XI PAI-1, tpa levels and polymorphisms CBC, CD55/59, JAK-2 (exon 12, CALR) 29

30 30

Thrombophilia: To test or not to test

Thrombophilia: To test or not to test Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical

More information

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri

More information

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine Scott M. Stevens, MD Co-Director, Thrombosis Clinic Intermountain Medical Center Associate Professor of Clinical Medicine The University of Utah School of Medicine No Relevant Financial Relationships Research

More information

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota Disclosures Financial interests

More information

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University

DISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)

More information

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective

More information

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?

More information

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis

More information

Approach to Thrombosis

Approach to Thrombosis Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation

More information

Are there still any valid indications for thrombophilia screening in DVT?

Are there still any valid indications for thrombophilia screening in DVT? Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016

More information

Laboratory Evaluation of Venous Thrombosis Risk

Laboratory Evaluation of Venous Thrombosis Risk Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic

More information

Original Policy Date

Original Policy Date MP 2.04.71 Genetic Testing for Inherited Thrombophilia Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search12:2013 Return to

More information

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000

Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures

More information

Optimal Utilization of Thrombophilia Testing

Optimal Utilization of Thrombophilia Testing Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine

More information

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism

More information

Menopausal Hormone Therapy & Haemostasis

Menopausal Hormone Therapy & Haemostasis Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen

More information

THROMBOSIS RISK FACTOR ASSESSMENT

THROMBOSIS RISK FACTOR ASSESSMENT Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)

More information

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be

More information

Updates in Diagnosis & Management of VTE

Updates in Diagnosis & Management of VTE Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE

More information

Duration of anticoagulation

Duration of anticoagulation Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,

More information

DOACs in SPECIAL POPULATIONS

DOACs in SPECIAL POPULATIONS DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy

More information

Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden

Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Inaugural meeting of Iranian Society on Thrombosis and Haemostasis Mofid Children Hospital Tehran, 24 December 2015 Chest. 2012;141(2_suppl):e48S-e801S

More information

Thrombophilias: A Practical Approach

Thrombophilias: A Practical Approach Disclosures Thrombophilias: A Practical Approach Speaker s Bureau: BMS/Pfizer (Apixaban) PI Altru Health System: EVE Trial Apixaban in Malignancy Keith E Swanson MD North Dakota Family Medicine Conference,

More information

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist

Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March

More information

THROMBOPHILIA SCREENING

THROMBOPHILIA SCREENING THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis

More information

Potpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy

Potpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Potpourri of Hematology Oncology Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Lifestyle Modifications to Decrease the Risk of Colorectal Cancer Estimates for 2018 American

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

Sinus and Cerebral Vein Thrombosis

Sinus and Cerebral Vein Thrombosis Sinus and Cerebral Vein Thrombosis A Summary Sinus and cerebral vein clots are uncommon. They can lead to severe headaches, confusion, and stroke-like symptoms. They may lead to bleeding into the surrounding

More information

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria

Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase

More information

ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation

ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of

More information

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following

More information

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE

More information

Lupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid

Lupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid , Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update William L. Nichols, MD Mayo Clinic College of Medicine Rochester, Minnesota USA Disclosures & Objectives (Nichols) Disclosures Relevant

More information

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular

More information

Duration of Therapy for Venous Thromboembolism

Duration of Therapy for Venous Thromboembolism Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee

More information

Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD

Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH TO T HROMBOPHILIA W ORKUPS & FRESH F ROZEN P LASMA U SE Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Learning Objectives AFTER COMPLETION

More information

New Developments in VTE Treatment

New Developments in VTE Treatment Disclosures: Accommodation at this meeting funded by Boehringer Investigator in phase III studies of Rivaroxiban, Dabigatran, Edoxaban New Developments in VTE Treatment GPCME meeting, August, Dunedin Dr

More information

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:

More information

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine

More information

Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A.

Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A. Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data Kenneth A. Bauer, MD kbauer@bidmc.harvard.edu Disclosures Janssen rivaroxaban BMS apixaban Boehringer

More information

How long to continue anticoagulation after DVT?

How long to continue anticoagulation after DVT? How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in

More information

Low-Molecular-Weight Heparin

Low-Molecular-Weight Heparin Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs

More information

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders

Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is

More information

PE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management

PE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management PE service Regional College Lecture PE Management Update in medicine (Eastern) Cambridge 29 th June 2017 Dr Rachel M Limbrey DM FRCP University Hospital Southampton NHS Foundation Trust Ambulatory acute

More information

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS

Thrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis

More information

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis

More information

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)

More information

Thrombosis. By Dr. Sara Mohamed Abuelgasim

Thrombosis. By Dr. Sara Mohamed Abuelgasim Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood

More information

Is Thrombophilia Testing Useful?

Is Thrombophilia Testing Useful? CONSULTATIVE HEMATOLOGY I: COMMON QUESTIONS IN THROMBOSIS CONSULTS Is Thrombophilia Testing Useful? Saskia Middeldorp 1 1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

More information

Diagnosis and management of heritable thrombophilias

Diagnosis and management of heritable thrombophilias Link to this article online for CPD/CME credits Diagnosis and management of heritable thrombophilias Peter MacCallum, 1 2 Louise Bowles, 2 David Keeling 3 1 Wolfson Institute of Preventive Medicine, Barts

More information

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior

More information

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior

More information

Understanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal

Understanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria

More information

Antiphospholipid antibodies

Antiphospholipid antibodies CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE Antiphospholipid Antibodies Caron P. Misita, PharmD; Stephan Moll, MD Antiphospholipid antibodies (APLAs) are proteins that may be present in the blood and

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None Genetic Testing for Inherited Thrombophilia Description Inherited thrombophilias are a group of disorders that predispose

More information

Perioperative Management of the Anticoagulated Patient

Perioperative Management of the Anticoagulated Patient Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center

More information

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,

More information

Sindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy

Sindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy Sindrome da anticorpi antifosfolipidi: clinica e terapia Vittorio Pengo Clinical Cardiology, Padova, Italy Revised Classification Criteria for the Antiphospholipid Syndrome J Thromb Haemost 2006;4:295-306

More information

Mohammadreza Tabatabaei IBTO COAG LAB

Mohammadreza Tabatabaei IBTO COAG LAB Tests for the Evaluation of Lupus Anticoagulants t Mohammadreza Tabatabaei MSc Hematology blood bank MSc Hematology blood bank IBTO COAG LAB Lupus Anticoagulants General Background Lupus anticoagulants

More information

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic

More information

Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. [Groningen]: Rijksuniversiteit Groningen.

Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. [Groningen]: Rijksuniversiteit Groningen. University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.

More information

Venous Thromboembolic Disease Update

Venous Thromboembolic Disease Update Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada

More information

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the

More information

Homocysteine is a chemical in

Homocysteine is a chemical in CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE Homocysteine and MTHFR Mutations Relation to Thrombosis and Coronary Artery Disease Elizabeth A. Varga, MS; Amy C. Sturm, MS; Caron P. Misita, PharmD; Stephan

More information

Predicting the risk of recurrent venous thromboembolism (VTE)

Predicting the risk of recurrent venous thromboembolism (VTE) J Thromb Thrombolysis (2015) 39:353 366 DOI 10.1007/s19-015-1188-4 Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business

More information

Top Ten Reasons For Failure To Prevent Postoperative Thrombosis

Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical

More information

WGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège

WGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège WGA meeting 2016 Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège Clinical question Which complementary investigations are you going to plan during or early after hospitalization

More information

Should Patients with Venous Thromboembolism Be Screened for Thrombophilia?

Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability

More information

Venous Thromboembolism: Principles of Outpatient and Inpatient Management

Venous Thromboembolism: Principles of Outpatient and Inpatient Management Venous Thromboembolism: Principles of Outpatient and Inpatient Management August 1, 2017 Seth Maliske, M.D. Internal Medicine Aspirus Wausau Hospital Disclosures/Conflicts of Interest I have no financial

More information

Absence of the Factor V Leiden mutation and genetic risk for CTEPH

Absence of the Factor V Leiden mutation and genetic risk for CTEPH Absence of the Factor V Leiden mutation and genetic risk for CTEPH Mark W. Dodson, MD, PhD Assistant Professor, Pulmonary/Critical Care Intermountain Medical Center Murray, Utah A paradox in our current

More information

Chapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families

Chapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin

More information

The Antiphospholipid Syndrome

The Antiphospholipid Syndrome The Antiphospholipid Syndrome 1 / 6 2 / 6 3 / 6 The Antiphospholipid Syndrome Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease present mostly

More information

Anticoagulant Therapy During Pregnancy

Anticoagulant Therapy During Pregnancy Anticoagulant Therapy During Pregnancy AIM - June 2007 Russell K. Laros, Jr., MD Thromboembolism and Pregnancy Leading Non-Obstetrical Cause of Maternal Mortality Early recognition and proper treatment

More information

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren

Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker

More information

Faculty Disclosure. Hypercoagulable States. Learning Objectives. Hereditary Thombophilia. Acquired Hypercoagulable States 5/9/2016

Faculty Disclosure. Hypercoagulable States. Learning Objectives. Hereditary Thombophilia. Acquired Hypercoagulable States 5/9/2016 Faculty Disclosure Hypercoagulable States Dr. Rizal has no actual or potential conflict of interest associated with this presentation By: Dr. Anuja Rizal Pharm. D., RPh., CACP Clinical Coordinator UConn

More information

Epidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione

Epidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations

More information

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017

Venous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017 Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in

More information

Keep catheter. Anticoagulate. Yes. Symptoms resolved? Yes. No Catheter needed? Other access sites available? Yes. Anticoagulate. Place new catheter

Keep catheter. Anticoagulate. Yes. Symptoms resolved? Yes. No Catheter needed? Other access sites available? Yes. Anticoagulate. Place new catheter Chief Anticoagulation and Thrombosis Service UCSF, SF VA MED CTR Thromboembolism Q&A Management of the Hospitalized Patient, SF, CA October 2012 CASES & ANSWERS 1. A 55 year old woman being treated for

More information

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer

More information

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital

More information

Venous thromboembolism (VTE) consists of deep vein

Venous thromboembolism (VTE) consists of deep vein Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders Richard D. Press, MD, PhD; Kenneth A. Bauer, MD; Jody L. Kujovich, MD; John A. Heit, MD

More information

COAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)

COAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin) COAGULATIONS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin) Haemostasis-blood must be maintained in a fluid state in order to function as a transport system, but must be able to solidify to form a clot following

More information

Thrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD

Thrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD Thrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD Corresponding author Stephan Moll, MD Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine, CB7035,

More information

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:

10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy: Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division

More information

This chapter will describe the effectiveness of antithrombotic

This chapter will describe the effectiveness of antithrombotic Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,

More information

Venous thromboembolism (VTe) affects approximately

Venous thromboembolism (VTe) affects approximately The Journal of The american osteopathic association Duration of Anticoagulation Treatment in Patients With Venous Thromboembolism Scott Kaatz, DO, MSc; Waqas Qureshi, MD; Christopher Fain, DO; and David

More information

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?

3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic? Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer

More information

Molecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer

Molecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer Molecular mechanisms & clinical consequences of prothrombin mutations A.J. Hauer 07-12-2018 Prothrombin & the coagulation cascade Coagulation factor II, thrombin. Prothrombin is synthesized in the liver

More information

Venous Thrombosis in Asia

Venous Thrombosis in Asia Venous Thrombosis in Asia Pantep Angchaisuksiri, M.D. Professor of Medicine, Mahidol University, Thailand Adjunct Associate Professor, University of North Carolina, Chapel Hill, USA Venous Thromboembolism

More information

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels

More information

Anticoagulation Forum: Management of Tiny Clots

Anticoagulation Forum: Management of Tiny Clots Anticoagulation Forum: Management of Tiny Clots Casey O Connell, MD FACP Associate Professor Jane Anne Nohl Division of Hematology Keck School of Medicine USC DISCLOSURES None 4/11/2017 Objectives Define

More information

Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)

Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain

More information

Thrombophilia testing in patients with venous thrombosis

Thrombophilia testing in patients with venous thrombosis Thrombophilia testing in patients with venous thrombosis Joseph A. Caprini, MD, Sofia Goldshteyn, MD, Catherine J. Glase, BS, Karen Hathaway, BS, Evanston and Chicago, IL. Department of Surgery Evanston

More information

Venous thrombosis in unusual sites

Venous thrombosis in unusual sites Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers

More information

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Thursday, October 11, 2018, 2:00pm ET Guest Speakers: Geoff Barnes, MD Scott Damrauer, MD Moderators: Tracy Minichiello, MD; Sara

More information

Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)

Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Ara Metjian, MD Duke Debates Benign Hematologic Highlights April 22, 2017 Disclaimer

More information

Adaptation of Published Heritable Thrombophilia Testing Guidelines into Local Practice

Adaptation of Published Heritable Thrombophilia Testing Guidelines into Local Practice Adaptation of Published Heritable Thrombophilia Testing Guidelines into Local Practice Tyler Smith, PGY-5, UBC Hematopathology Supervisor: Dr. A. Lee Collaborators: Dr. D. Pi, Dr. M. Hudoba 2011 CADTH

More information